CELLECTISAct. Nom. Aktie
| 1,82EUR | -0,07EUR | -3,71% |
WKN DE: A0MKPR / ISIN: FR0010425595
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 71,42 |
| AstraZeneca PLC | 15,98 |
| Bpifrance Participations SA /PRIVATE EQUITY/ | 5,87 |
| Pfizer Inc. | 2,78 |
| Pierre Bastid | 1,80 |
| Baillie Gifford & Co. | 1,35 |
| CDC Croissance SA | 1,04 |
| André Choulika, PhD | 1,02 |
| David J. Sourdive, PhD | 0,99 |
| American Funds Small Cap World Fund | 0,76 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 264 | 281 | 294 | 237 | 221 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,05 | 0,23 | 0,16 | 0,08 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 349 | 258 | 198 | 114 | 211 |
| Summe Anlagevermögen | 68 | 126 | 138 | 130 | 92 |
| Summe Aktiva | 416 | 384 | 336 | 245 | 303 |
Bilanz (in Mio. EUR) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 42 | 87 | 89 | 71 | 84 |
| Summe Fremdkapital | 100 | 131 | 128 | 127 | 226 |
| Summe Eigenkapital | 317 | 252 | 208 | 118 | 77 |
| Summe Passiva | 416 | 384 | 336 | 245 | 303 |
Adresse
| 8, rue de la Croix Jarry, 75013 Paris | |
| Telefon | +33 (1) 81-69-16-00 |
| Fax | +33 (1) 81-69-16-06 |
| Internet | http://www.cellectis.com |
Management
|
Adrian Kilcoyne
Chief Medical Officer |
|
André Choulika
Chief Executive Officer & Director |
|
Arthur Stril
Chief Financial & Business Officer |
|
Axel-Sven Malkomes
Independent Director |
|
Cécile Chartier
Director |
|
David J. Sourdive
Director & Executive VP-CMC & Manufacturing |
|
Donald A. Bergstrom
Independent Director |
|
Jean-Pierre Garnier
Non-Executive Chairman |
|
Kyung Nam-Wortman
Chief Human Resources Officer & Executive VP |
|
Laurent Arthaud
Independent Director |
|
Marc Pierre Jean Dunoyer
Director |
|
Marie-Bleuenn Terrier
Secretary & General Counsel |
|
Philippe Duchateau
Chief Scientific Officer |
|
Pierre Bastid
Independent Director |
|
Rainer J. Boehm
Independent Director |
|
Stephan Reynier
Chief Regulatory & Compliance Officer |
|
Steve Doares
Senior Vice President-US Manufacturing |
|
Tyrell J. Rivers
Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
